Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Current Leases (2019 - 2025)

Historic Current Leases for Protagonist Therapeutics (PTGX) over the last 7 years, with Q3 2025 value amounting to $2.2 million.

  • Protagonist Therapeutics' Current Leases rose 485111.11% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 485111.11%. This contributed to the annual value of $510000.0 for FY2024, which is 5530.24% down from last year.
  • Per Protagonist Therapeutics' latest filing, its Current Leases stood at $2.2 million for Q3 2025, which was up 485111.11% from $2.2 million recorded in Q2 2025.
  • Over the past 5 years, Protagonist Therapeutics' Current Leases peaked at $2.6 million during Q1 2023, and registered a low of $45000.0 during Q3 2024.
  • Over the past 5 years, Protagonist Therapeutics' median Current Leases value was $2.1 million (recorded in 2021), while the average stood at $1.8 million.
  • Its Current Leases has fluctuated over the past 5 years, first crashed by 9750.42% in 2024, then surged by 485111.11% in 2025.
  • Quarter analysis of 5 years shows Protagonist Therapeutics' Current Leases stood at $2.2 million in 2021, then increased by 14.32% to $2.5 million in 2022, then plummeted by 54.63% to $1.1 million in 2023, then tumbled by 55.3% to $510000.0 in 2024, then surged by 336.86% to $2.2 million in 2025.
  • Its Current Leases stands at $2.2 million for Q3 2025, versus $2.2 million for Q2 2025 and $1.6 million for Q1 2025.